Yellow fever future or investigational therapies: Difference between revisions
| Line 15: | Line 15: | ||
[[Category:Hepatology]] | [[Category:Hepatology]] | ||
[[Category:Infectious disease]] | [[Category:Infectious disease]] | ||
[[Category:Viral diseases]] | |||
[[Category:Flaviviruses]] | |||
[[Category:Tropical disease]] | |||
[[Category:Insect-borne diseases]] | |||
[[Category:Neglected diseases]] | |||
{{WikiDoc Help Menu}} | {{WikiDoc Help Menu}} | ||
{{WikiDoc Sources}} | {{WikiDoc Sources}} | ||
Revision as of 16:47, 7 December 2012
|
Yellow fever Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Treatment |
|
Yellow fever future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of Yellow fever future or investigational therapies |
|
Yellow fever future or investigational therapies in the news |
|
Risk calculators and risk factors for Yellow fever future or investigational therapies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Current Research
In the hamster model of yellow fever, early administration of the antiviral ribavirin is an effective early treatment of many pathological features of the disease.[1] Ribavirin treatment during the first five days after virus infection improved survival rates, reduced tissue damage in target organs (liver and spleen), prevented hepatocellular steatosis, and normalized alanine aminotransferase (a liver damage marker) levels. The results of this study suggest that ribavirin may be effective in the early treatment of yellow fever, and that its mechanism of action in reducing liver pathology in yellow fever virus infection may be similar to that observed with ribavirin in the treatment of hepatitis C, a virus related to yellow fever.[1] Because ribavirin had failed to improve survival in a virulent primate (rhesus) model of yellow fever infection, it had been previously discounted as a possible therapy.[2] In 2007 the World Community Grid launched a project where by computer modeling of the Yellow Fever Virus (and related viruses) thousands of small molecules are screened for their potential anti-viral properties in fighting Yellow Fever. This is the first project to utilize computer simulations in seeking out medicines to directly attack the virus once a person is infected. This is a distributed process project similar to SETI@Home where the general public downloads the World Community Grid agent and the program (along with thousands of other users) screens thousands of molecules while their computer would be otherwise idle. If the user needs to use the computer the program sleeps. There are several different projects running, including a similar one screening for anti-AIDS drugs. The project covering Yellow Fever is called "Discovering Dengue Drugs – Together." The software and information about the project can be found at:
References
- ↑ 1.0 1.1 Sbrana E, Xiao SY, Guzman H, Ye M, Travassos da Rosa AP, Tesh RB (2004). "Efficacy of post-exposure treatment of yellow fever with ribavirin in a hamster model of the disease". Am J Trop Med Hyg. 71 (3): 306–12. PMID 15381811.
- ↑ Huggins JW (1989). "Prospects for treatment of viral hemorrhagic fevers with ribavirin, a broad-spectrum antiviral drug". Rev Infect Dis. 11 Suppl 4: S750–61. PMID 2546248.